GENE ONLINE|News &
Opinion
Blog

2022-01-26| Funding

Google-Backed Leyden Labs Closes $140 Million Series B to Fight Viruses with Nasal Spray

by Joy Lin
Share To

Dutch biotech Leyden Labs may have been founded in the early days of the Covid-19 pandemic, but that didn’t stop it from raising $200 million in 2021 to fund the development of treatments against respiratory viruses. The firm recently completed a $140 million Series B financing round led by Series A investors Casdin Capital and GV (formerly known as Google Ventures). 

The fundraising round welcomed new investors such as Softbank Vision Fund 2, Invus, and Bluebird Capital, as well as existing Series A investors F-Prime Capital and Byers Capital/ Brook Byers. 

Additionally, Eli Casdin of Casdin Capital will join Leyden’s board of directors, while Vali Barsen of Softbank Investment Advisers, Jeff Bird of Bluebird Ventures, and Suzanne Jung Angell of Casdin Capital will join the Board as observers. 

The cash injection will go into Leyden’s platform and portfolio development, as well as team expansion.  

Related Article: GeneOnline’s Pick: Notable Novel FDA Approved Drugs in 2021

Anti-Influenza Antibody Licensed from Johnson and Johnson

 

Leyden’s lead candidate is PanFlu, an intranasal spray that delivers CR9114, a human monoclonal antibody that fights against influenza A and B. CR9114 was licensed from Janssen, a Johnson and Johnson company, last week. Under the deal, Leyden paid Janssen an undisclosed sum, and will also make milestone payments in exchange for a worldwide license to develop and market the drug, which can be administered through the nose and throat. 

Last July, Leyden began a partnership with UK-based company Nanopharm to develop nasal sprays for respiratory viruses.

©www.geneonline.com All rights reserved. Collaborate with us: service@geneonlineasia.com
Related Post
Pharmaceutical Giants Expand Research and Manufacturing Capabilities, Fueling 2024 Innovation and Growth
2024-03-01
FDA Boxed Warning for CAR-T therapy, Affecting Bristol-Myers Squibb, Novartis, Janssen, Gilead Sciences
2024-01-24
JPM 2024: Biotech Companies Mapping Out Their Future, and a New Round of M&A Spree Begins
2024-01-09
LATEST
Company Presentations at BIO 2024 Inspire Partnering
2024-06-14
GV Regains Compliance with Nasdaq Minimum Bid Price Requirement
2024-06-13
ARPA-H Fast-Tracks Biotech Startups: Funding Insights from BIO 2024 Panel
2024-06-12
Gene Therapy Innovations and Financial Challenges for the Future of Medicine
2024-06-12
BIO Releases DEI Survey in Partnership with Korn Ferry
2024-06-11
Advancing Healthcare Accessibility and Sustainable Development
2024-06-11
New CRISPR Method Enables Gene Edits in Cockroaches and All Insects
2024-06-11
EVENT
Scroll to Top